---
title: "ADC Therapeutics completes LOTIS-7 Phase 1b enrollment for Zynlonta-glofitamab combo in r/r DLBCL"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291272696.md"
description: "ADC Therapeutics has completed enrollment in the LOTIS-7 Phase 1b trial evaluating Zynlonta combined with Roche’s Columvi for relapsed or refractory diffuse large B-cell lymphoma. Early results indicate strong tumor shrinkage and manageable side effects, with full data expected in Q4 2026. The company plans to assess regulatory pathways for potential broader adoption."
datetime: "2026-06-30T11:15:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291272696.md)
  - [en](https://longbridge.com/en/news/291272696.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291272696.md)
generator: "portal-rs"
---

# ADC Therapeutics completes LOTIS-7 Phase 1b enrollment for Zynlonta-glofitamab combo in r/r DLBCL

-   ADC Therapeutics completed enrollment in the LOTIS-7 Phase 1b trial testing ZYNLONTA with Roche’s COLUMVI in relapsed or refractory DLBCL. \* Early study results have already been presented, showing strong tumor shrinkage rates with side effects viewed as manageable. \* Full results will be presented in Q4 2026, with publication targeted by end-2026. \* The company plans to evaluate regulatory and compendia options, signaling a potential push toward broader adoption if later data hold up. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606300715PR\_NEWS\_USPR\_\_\_\_\_NY94994) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [ADC Therapeutics posts corporate presentation highlighting Zynlonta growth opportunity in B-cell lymphomas](https://longbridge.com/en/news/295800995.md)
- [ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss](https://longbridge.com/en/news/295792525.md)
- [ADCT: Q2 2026 delivered stable sales, improved losses, and regulatory challenges for ZYNLONTA](https://longbridge.com/en/news/295792223.md)
- [ADC Therapeutics Q2 loss narrows; cuts 17% workforce](https://longbridge.com/en/news/295791965.md)
- [Bank of America Securities Keeps Their Buy Rating on Agree Realty (ADC)](https://longbridge.com/en/news/296102817.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**